Generic name |
secukinumab |
---|---|
Strength |
150 mg/mL |
Form |
Solution for subcutaneous injection |
Special Authority criteria |
Approval period |
---|---|
For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form 5380. Coverage of secukinumab for the treatment of plaque psoriasis is only available when prescribed by a dermatologist. |
First approval: 12 weeks Renewal: 1 year |
For the treatment of ankylosing spondylitis, according to established criteria described in Special Authority request forms 5365 (initial/switch) and 5366 (renewal). Coverage of secukinumab for the treatment of ankylosing spondylitis is only available when prescribed by a rheumatologist. |
First approval: 1 year Renewal: 1 year |
For the treatment of psoriatic arthritis, according to established criteria described in Special Authority request forms 5360 (initial/switch) and 5361 (renewal). Coverage of secukinumab for the treatment of psoriatic arthritis is only available when prescribed by a rheumatologist. |
First approval: 1 year Renewal: 1 year |
See practitioner/prescriber requirements above